C A Anuradha,
Jithan Aukunuru 
For correspondence:- Jithan Aukunuru Email: aukunjv@gmail.com Tel:00918702455111
Received: 17 June 2009 Accepted: 19 December 2009 Published: 23 February 2010
Citation: Anuradha CA, Aukunuru J. Preparation, Characterisation and In vivo Evaluation of Bis-demethoxy Curcumin Analogue (BDMCA) Nanoparticles. Trop J Pharm Res 2010; 9(1):51-58 doi: 10.4314/tjpr.v9i1.7
© 2010 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To fabricate biodegradable nanoparticle formulation of bis-demethoxy curcumin analogue (BDMCA), a novel curcumin analogue, and evaluate its in vitro and in vivo characteristics.
Methods: Nanoparticle formulations were fabricated by a double emulsion solvent evaporation technique using polycaprolactone as the polymer. The nanoparticles were characterised for drug content, particles size, in vitro drug release and the drug-polymer interaction. The in vivo properties of the formulations in male Wistar rats were evaluated from the pharmacokinetics and pharmacodynamics of BDMCA following i.v. administration of the nanoparticles. BDMCA solution was administered i.v. as a reference. Hepatoprotectivity of the formulation was determined in a CCl4-treated rat model.
Results: The BDMCA nanoparticles were successfully prepared using double emulsion solvent evaporation technique. The nanoparticle formulations effectively sustained the release of the drug for more than 10 days both in vitro and in vivo. They also offered better pharmacokinetic properties to the drug than that afforded by the free drug itself. Intravenous nanoparticular administration reversed serum liver enzyme levels by 90%, compared to 52 % for repeated i.v. administration of the solution form.
Conclusion: BDMCA particle demonstrated good pharmacokinetic and pharmacodynamic properties following i.v. administration.
Archives
News Updates
Fulltext in PDF